In order to find the best method of prevention for the Covid-19 epidemic, preclinical trials evaluating the safety and ability to generate an immune response of the Nanocovax Vaccine were fully and thoroughly performed by Nanogen. research and testing according to scientific standards to create a solid and safe basis for further trials on humans.
Experimental animals were pig-tailed monkeys, mice, rats, guinea pigs and rabbits. The test is conducted according to scientific standards, ensuring the strict and safe process of the Ministry of Health.
The test results show that, after injecting the Nanocovax sample:
Mice did not have abnormal expressions, ate, worked normally, and all gained weight during the test. Notice that there is a statistically significant difference when comparing the weight of mice before and after the test; no abnormalities and differences in the external shape and color of the heart, liver, kidney, lung and digestive system when observed macroscopically; Microscopic examination of liver structure showed no abnormal signs, congestion, or necrosis in all experimental groups.
For rabbits, in the first 2 hours after injection, only 1 test rabbit showed mild swelling and redness at the injection site in both groups: Nanocovax sample and placebo group. These manifestations gradually increased from 4 hours after injection and showed swelling, redness at the injection site most clearly at 24 hours after injection. However, the phenomenon gradually decreased and disappeared after 5 days.
Monkeys gained slight weight during the 28-day follow-up period. After injecting the Nanocovax sample for about 10-15 minutes, the monkeys all showed signs of itching, itching appeared in about 20-25 minutes. After a period of itching, monkeys eat and drink normally. Observe the injection site, see that within 1 hour after injection, the injection site is slightly red, there is no sign of swelling or inflammation. After 24 hours, all injections were normal, with no redness, swelling, itching or pain. Temperature monitoring results: no significant temperature change within 28 days.
Based on the above results, Nanocovax meets the standards of preclinical testing. This is an important first step for Nanogen to bring Nanocovax into the current phase 3 clinical trial.
Results of preclinical trials on monkeys of Nanocovax vaccine: see more here
Results of preclinical trials on mice and rabbits of Nanocovax vaccine: see more here
